Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks

Moderna, BioNTech, CureVac and Novavax have added billions of dollars in combined market capitalization gains in recent days after two cases of bird flu were reported in humans in the U.S. and reports emerged of a potential federal government vaccine program. On Wednesday, Moderna gained 14% while BioNTech added 11%. CureVac jumped 19%.